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Abstract

Acute pain is categorized by a length of 3 to 6 months, is directly related to soft
tissue damage, and gradually resolves as the injured tissues heal. Chronic pain is
defined as any pain lasting longer than 12 weeks. Over 100 million Americans suffer
from chronic pain, and the health care costs and productivity losses approach $635
billion annually (Institute of Medicine Committee on Advancing Pain Research and
Education, 2011). The lack of clear quality standards for ethical/legal use of opiates,
the presence of individuals abusing the system, and the lack of updated, and
involved public policy make finding a doctor willing to treat chronic pain quite
difficult. During a personal struggle with chronic pain, I participated in a 10-week
program consisting of education about chronic pain and common treatments, yoga
and other strengthening and movement-oriented exercises, and recent research on
chronic pain and corresponding treatments. I learned about many new, alternative
ways to fix my body, reduce my pain, and help me live a better life. The purpose of
this project is to bring awareness to the prevalence of chronic pain, the truth about
current treatments, and education about alternative treatments.
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Chronic Pain: Physiological Foundations, Psychological Effects, Common
Treatments, and New Directions
During June of 2016, I began experiencing debilitating, constant pain
throughout my lower back. No injuries or accidents seemed to be the cause and
there was no easily identified reason I should be feeling severe pain. Over the course
of a few months, I saw multiple doctors concerning my back pain. One suggested
this was the result of normal aging, despite only being 20 years old. Others simply
gave me a 2-day prescription of small doses of muscle relaxers.
Following months of failed attempts to get some pain relief, a doctor finally
took an x-ray and found that I have a mild case of scoliosis. Scoliosis itself does not
typically cause pain, but the lack of stability in my spine caused my muscles to take
the brunt of my hard, physical work and caused me immense pain. Surgery would be
too risky in my case, as the curve of my spine begins in the lumbar region.
I was prescribed a long list of prescriptions medications and began opioid
therapy. Eventually, I was referred to a clinic that worked with chronic pain
patients. I participated in a 10-week program consisting of education about chronic
pain and different common treatments, Acceptance and Commitment Therapy
(ACT), and yoga/other strengthening and movement-oriented exercises. The onset
of my chronic pain and my journey through treatment made me aware of the
prevalence of chronic pain in the United States and the efforts in the medical field to
find adequate treatments for chronic pain.
Chronic pain is a pervasive health issue that many people around the world
experience, which exacts major costs on personal quality of life and society.
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According to the National Institute on Drug Abuse, over 100 million Americans
suffer from chronic pain, and the Institute of Medicine Committee on Advancing
Pain Research and Education report that health care costs and work productivity
losses approach $635 billion annually (Institute of Medicine, 2011).
Pain can manifest in many forms and is classified as acute or chronic. Acute
pain is expected during the recovery period following injury. When pain persists
longer than 12 weeks and impedes daily function it is referred to as chronic pain.
Although the source of the pain may be similar, chronic pain states are different
from acute pain in underlying mechanisms, symptomatology, and treatment
responses. Recent research on human and animal subjects have shown that the
brain undergoes structural changes to the reward circuits within the brain when
experiencing chronic pain, affecting functionality and activity in those sites
(Navratilova et al., 2016). As pain progresses from acute to chronic, pain sensitivity
is exacerbated by negative emotional states and comorbidities such as depression,
anxiety, anhedonia, sleep disturbance, decision-making abnormalities, and suicide
risk are common (Navratilova et al., 2016). Many researchers have uncovered
correlations between chronic pain and poor perception of health, lower functional
capacity, poor social relationships, isolation, financial difficulties, and higher
healthcare expenses (Butchart et al., 2009; Morasco et al., 2011).
In addition to the physical pain and comorbid negative affect, many chronic
pain patients also encounter stigma associated to chronic pain patients. Often
resulting from cases where medical imaging is unable to locate a specific source of
the pain, stigma surrounding chronic pain patients is manifest in judgement, blame,
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or disbelief from health care professionals, the larger community, friends and
family, and the workplace (Slade et al., 2009). Judgements assuming malingering or
pursuit of some gain leave chronic pain patients hesitant to seek care, creating an
additional roadblock to pain relief.
As the societal costs grow, the motivation to find adequate relief from
chronic pain is widespread. With the establishment of the “Decade of Pain Control
and Research” in 2000, the use of opioids to treat pain became more commonplace,
and opioids continue to be the most common treatment used to treat chronic pain
(Krashin et al., 2013). This has resulted in a growing epidemic of opioid use in the
United States and has encouraged research into alternative treatments for chronic
pain. Psychological methods of cognitive and behavioral therapy have been used to
treat chronic pain and comorbid affective disorders. In addition, research into
medical cannabis has added to the progress toward pharmaceutical-free relief of
chronic pain. Findings suggest that increasing safe access to medical cannabis may
reduce the growing problematic use of pharmaceutical opiates, and can reduce
harms associated with addiction (Lucas, 2012).
While the array of treatment options for chronic pain patients is expanding,
many of the common treatments for pain are often inadequate in isolation, and
make it hard to manage comorbid conditions in addition to the source of pain. The
treatment methods covered are those with the largest bodies of available research.
Through analysis of the structural brain changes resulting from chronic pain, as well
as various common treatments, it is clear that the best approach to chronic pain
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treatment is interdisciplinary, integrating multiple treatment approaches to address
chronic pain.
Comorbidity
Chronic pain can have many possible sources and many different
manifestations. For many cases, nonmalignant pain originating from soft tissues or
neuropathy cannot be seen with diagnostic imaging techniques. The lack of
objective evidence can delegitimize the suffering of the patient: many chronic pain
patients are labeled as suffering from psychosomatic symptoms (symptoms
originating from a psychological factor), implying that the physical symptoms are
not real (Ablin & Buskila, 2012). Portenoy et al. (2004) argue that although pain
originating exclusively from psychological factors does occur, it is still less prevalent
than pain associated with body processes that are influenced by psychosocial
factors and comorbid psychiatric conditions. Attributing pain to psychosomatic
sources is an incomplete answer without established cause.
The incorrect attribution of pain to psychosomatic sources is further
complicated by the actual prevalence of psychological disorders co-occurring with
chronic pain. Asmundson and Katz (2012) found that among adults from 17
countries, those with chronic back or neck pain are two or three times more likely to
have experienced panic disorder, agoraphobia, or social anxiety disorder, and three
times more likely to have generalized anxiety disorder or post-traumatic stress
disorder. Depression has also been shown to increase pain intensity and duration,
as well as negatively affect pain treatment outcomes (Garland et al., 2014). These
results were corroborated by findings that chronic pain patients with anxiety or
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depression tend to have more physical symptoms and that, as the quantity of
symptoms increases, so does the likelihood of an anxiety disorder or depression
(Kroenke et al., 1994). Gureje et al. (2001) found this same pattern cross-culturally.
Chronic pain patients are also three times as likely to experience suicidal ideation as
compared to the general population (Tang & Crane, 2006). These findings support
the notion that chronic pain and psychological disorders often co-occur. The
frequent co-occurrence is likely due to the chronic pain and psychiatric symptoms
influence one another in a mutually maintaining way, in that the pain exacerbates
the psychiatric symptoms and the psychiatric symptoms exacerbate the pain, or that
there is a third variable that acts on both the pain and mental health. These
possibilities are not mutually exclusive, making it harder to find the true driving
force. The truth is that the source of chronic pain is much too complex to be
considered simply psychosomatic.
The brain is integral to the experience of pain and to responses to pain.
Neuroimaging has provided a lot of information regarding how pain is processed in
the brain and the role that psychological disorders play in chronic pain. Navratilova
and colleagues (2016) used neuroimaging to investigate changes in brain processing
resulting from chronic pain, hoping to find a link between chronic pain and
depression, anxiety, anhedonia, sleep disturbance, and risk of suicide. The
hypothesis that motivation circuits were affected by chronic pain is based on the
concept that pain is a homeostatic emotion that causes autonomic responses similar
to other aversive states like hunger or fear.
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Researchers found that structural and functional changes occur in emotional
and reward circuitries in the brain and that chronic pain patients often process pain
in these affective circuits to a greater extent than those suffering from acute pain
with an ultimate recovery (Navratilova, et al., 2016). The findings highlight that as
pain persists, emotional circuits in the brain are changed, indicating a link between
the high incidence of chronic pain patients experiencing comorbid affective
disorders. Some patients truly do have comorbid psychiatric symptoms, while
others suffer from chronic widespread pain, yet do not suffer from psychiatric
symptoms. In individuals that do not experience comorbid psychiatric symptoms,
their intact mental health seems to be almost protective regarding their general
condition (Ablin & Baskila, 2012).
In response to the affirming evidence of the comorbidity of psychological
disorders and chronic pain, the current literature recognizes that “pain is a complex
perceptual experience determined by sensory as well as psychological and social
influences” (Asmundson & Katz, 2009, p. 889). In order to examine the complexities
of pain and comorbid disorders, a biopsychosocial model is used to better
understand health and illness through analyzing the complex interactions between
biological, psychological, and social factors (Gatchel, 2014). The biopsychosocial
approach asserts that to comprehensively assess a patient’s pain, it is necessary to
examine the interrelationships between biological changes, psychological wellbeing, and sociocultural environment (Gatchel, 2004).
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Opioid Treatment

For any pain not managed with over the counter medications such as aspirin,
ibuprofen, or acetaminophen, the common next option is treatment with opioids.
According to Bailey and Vowles (2015), “chronic pain is particularly challenging to
manage when it comes to opioids because most individuals will build tolerance to
the drug and any reduction in use is likely to produce withdrawal symptoms
(indicating dependence)” (p. 342). This creates the potential for significant
increases in opioid dependence based on predictions that the prevalence of chronic
pain will grow as the population ages.
The growth of opioid treatment began when President Clinton signed a law
dedicating the decade from 2000 to 2010 the “Decade of Pain Control and Research”
(Lippe, 2000). This decade saw the inclusion of pain as a vital sign and contributed
to a major increase in the use of opioid treatment resulting from a strong moral
argument to treat all chronic pain with opioids when other treatments failed to
provide adequate relief (Krashin et al., 2013). Many efficacy trials indicated that
opioid treatment is useful in reducing the intensity of neuropathic, nociceptive, and
musculoskeletal pain experience over a period of 6 months or less. This combination
of factors led to a rise in opioid prescriptions, as well as the prevalence of opioid
misuse, with misuse being defined as “use of a medication (for a medical purpose)
other than as directed or indicated, whether willful or unintentional, and whether
harm results or not” (Denisco et al., 2008). While the number of cases of opioid
misuse has leveled off in the past several years, the 2006 National Survey of Drug
Use and Health (NSDUH) shows increasing mortality associated with opioids,
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resulting from the increased availability of the medications, rather than misuse by
those prescribed them (SAMHSA, 2007). The NSDUH reports that 55.7% of those
who misused opioids said they received the medication from friends or family, and
that 80.7% reported that the friend or relative had obtained the opioids from one
doctor. Only 3.9% of respondents reported obtaining the drug from a drug dealer or
stranger, and 0.1% reported buying the drug from the Internet.
Chronic pain patients typically respond well to opioids initially, but regular
use is associated with long term complications including dependence, addiction, and
withdrawal. The DSM-V (APA, 2013) defines substance dependence as a
combination of three or more of the following symptoms within a 12-month period:
tolerance to the effects of a substance, withdrawal upon abrupt cessation, using
larger amounts than intended, spending a great deal of time on the substance,
limiting social, occupational, or recreational activities because of substance use, and
use despite psychological or physical problems from the substance. The American
Pain Society (2002) defined addiction as one or more of the following symptoms:
impaired control regarding the use of the drug, compulsive drug use, continued drug
use despite consequences, and unmanageable drug craving.
According to the Center for Disease Control and Prevention, in 2014
approximately 2 million Americans abused or were dependent on prescription
opioids. In 2016 a total of 42,249 individuals died of opioid overdose, approximately
115 individuals each day (CDC, 2017). Of the long-term users of prescription opioids
for chronic pain, the CDC reports that as many as 25% struggle with addiction. The
risk of dependence or death, coupled with the short-term success of opioid
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treatment, creates a dilemma for chronic pain patients and medical providers alike.
In the interest of safety, opioids began to be viewed as a form of comfort care for
patients who have exhausted all other treatment options and the prospect of
recovery (Krashin et al., 2013).
While the use of opioids can be costly on an individual basis, resulting in
addiction or dependence, the costs to the larger society are a close rival. According
to Birnbaum and colleagues (2011), workplace, health care, and criminal justice
costs totaled $55.7 billion in 2007. Workplace costs manifest in lost productivity,
premature death, lost wages/employment, presenteeism, and absenteeism. In 2007
the workplace costs totaled $25.6 billion, which is 46% of total societal costs. Health
care costs accounted for $25 billion, which consisted mainly of excess medical and
prescription costs. Criminal justice costs occurred in the form of correctional
facilities and police costs, totaling $5.1 billion (Birnbaum et al., 2011).
Ballantyne and Shin (2008) found that opioid treatment beyond three
months is not associated with sustained improvement in pain or function for most
patients, and that opioids are actually associated with worse functional and
occupational outcomes in cases of musculoskeletal pain. The collective findings that
addiction, overdose, and prescription diversion (medications not being taken by the
person prescribed them, often sold or given to others) are common results of opioid
therapy left the medical field and public policy makers struggling to address chronic
pain patients. The major challenge is to minimize the likelihood of opioid misuse,
without limiting the legitimate use of opioid medications. Attempts to control abuse
can result in discouraging treatment and restricting the medical profession
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(Rosenblum et al., 2008). Hesitancy to prescribe opioids also results from the
perceived and real risks of legal scrutiny regarding the prescribing of a controlled
substance (Rosenblum et al., 2008).
The current solution to the dilemma regarding opioid treatment is to identify
individuals who are at a higher risk of abuse, allowing those with low risk to receive
the medication while protecting those who are at high risk of addiction. A majority
of chronic pain patients who are exposed to chronic opioid analgesic therapy will
not develop addiction or abusive behaviors (3.27%, compared to 10% in the general
population), while the prevalence of patients who will demonstrate aberrant drugrelated behaviors (including not having prescribed medicines in urine, having
unprescribed drugs in urine, or other behaviors indicating abuse of or diversion of
opioids) is higher (11.5%) (Fishbain et al., 2008). If chronic pain patients are
screened for current or past history of alcohol or illicit drug use, abuse, or addiction,
the percentage of chronic pain patients misusing opioids is much lower (3.27% in
non-selected groups, as opposed to 0.19% in preselected groups) (Fishbain et al.,
2008). These findings highlight that the concept of de novo addiction (addiction
without a previous history of addiction) is rare with chronic opioid analgesic
therapy.
While evidence does support the efficacy of opioid treatment, it is important
to be aware that the results indicate short term success, and do not highlight longterm risks. It is also important to note that studies regarding opioid therapy lacked
inclusion of a control group given a placebo, a control with no opioid therapy, or a
control using a different, nonopioid therapy (Dowell et al., 2016). For this reason,
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opioid prescription should not be considered the gold standard. Treatment for
chronic pain should include other psychosocial interventions and possibly other
physical treatments to target the pain from multiple sides of the biopsychosocial
framework (Bailey & Vowles, 2015). Dowell et al. (2016) compiled a list of
recommendations regarding treatment of chronic pain including beginning with
nonpharmacological therapy or nonopioid pharmacologic therapy, establishing
treatment goals for pain and function, evaluating benefits and harms with the
patient, when beginning opioid therapy, begin with the lowest effective dose, and
considering periodic urine drug testing to assess possible misuse or diversion of
medications. In addition to these recommendations, multidisciplinary therapies can
help reduce pain and improve function more effectively than single modality
treatments (Dowell et al., 2016).
Medical Use of Cannabis
Beginning in 2015 the legalization of medical marijuana has swept across the
United States (Hill, 2015). Legalization facilitates access to marijuana as a treatment
for a variety of medical conditions. Medical marijuana has also been decriminalized
in Washington, Colorado, Alaska, Oregon, and Washington D.C. Meanwhile,
marijuana is still federally illegal: the U.S. Drug Enforcement Administration states
that until the FDA approves its use, cannabis is not considered a legitimate
medication. The DEA considers marijuana to be a precursor to abuse of other drugs,
and to be a danger to the user and to others. This is countered by research that
shows it is not cannabis itself that leads to further drug use, but rather the
combination of family history/predisposition to psychoactive substance use, early
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introduction to cannabis, more rapid progress towards regular use, frequenting
deviant environments, and availability of various substances from the same dealers
(Lucas, 2012). Despite arguments for or against its use, marijuana is the most
commonly used illicit drug in the United States, with 12% of people aged 12 years or
older reporting use in the last year. A declining perception of risk associated with
the spread of legalization has increased rates of use among teens (Hill, 2015).
While differentiated in name, medical and recreational marijuana are
identical in form. Both are dried material from the Cannabis plant, consisting of
tetrahydrocannabinol (THC), cannabidiol (CBD), and other cannabinoids (Hill,
2015). In contrast to THC, the psychoactive component of marijuana, CBD does not
involve the reward center in the brain, and has limited misuse or diversion
potential. CBD also has very low risks of causing mortality, reducing concerns
regarding potential overdose (Hurd, 2017). Human and animal studies show that
CBD can moderate anxiety via activation of the amygdala during negative emotional
processing (Hurd, 2017).
Medical marijuana is purchased from dispensaries in a variety of
preparations or grown by patients or licensed growers (because of its status as
federally illegal, medical marijuana cannot be obtained in pharmacies).
Cannabinoids can be administered orally, sublingually, or topically, smoked, inhaled,
mixed with food, or made into tea. Prescribed cannabinoids come in the form of
dronabinol capsules, nabilone capsules, and oromucosal spray nabiximols (Whiting
et al., 2015).
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Medical marijuana is commonly used to mitigate nausea and vomiting due to
chemotherapy, appetite stimulation in HIV/AIDS, chronic pain, spasticity due to
multiple sclerosis, depression, anxiety disorder, sleep disorder, psychosis,
intraocular pressure in glaucoma, and Tourette syndrome (Whiting et al., 2015). The
efficacy of medical marijuana varies widely by affliction, but shows high efficacy for
chronic pain, neuropathic pain, and spasticity due to multiple sclerosis (Hill, 2015).
Compared with placebo, cannabinoids are associated with greater reduction in pain
and a greater average reduction in numerical rating pain assessment (Whiting et al.,
2015). The average number of patients who reported a reduction in pain of at least
30% was also greater with cannabinoids than with placebo, with smoking having
the greatest beneficial effect. Comparisons of low THC cannabis and high THC
cannabis report that both methods are effective at reducing pain, with no clear
correlation between dose levels and pain relief (Lucas, 2012).
Common adverse reactions to marijuana use include asthenia, balance
problems, confusion, dizziness, diarrhea, dry mouth, nausea, fatigue, euphoria,
vomiting, disorientation, drowsiness, confusion, loss of balance, and hallucinations
(Whiting et al., 2015). Marijuana also impairs short-term memory, motor
coordination, and judgement, which double the risk of involvement in a motor
vehicle crash while driving (Hill, 2015). Paranoid ideation and psychotic symptoms
are rare, but can occur. Recent studies have found that occasional marijuana users
undergo structural brain changes in the nucleus accumbens and the amygdala. In
people younger than 20, brain development can be impaired, with regular
marijuana use affecting functional connectivity and possibly declining IQ. Regular
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marijuana use can also produce physical problems, including increased incidence of
chronic bronchitis, increase rates of respiratory tract infections and pneumonia.
There is also a potential link between regular marijuana use and heart attack,
stroke, and peripheral vascular disease. Before beginning medical marijuana,
patients should have exhausted other treatment options, and have no history of
substance use disorder, psychotic disorder, unstable mood disorder, or anxiety
disorder. Patients with conditions such as major depressive disorder, anxiety
disorders, and viral upper respiratory tract infections may find that marijuana use
exacerbates these conditions (Hill, 2015). Marijuana use comes with its own risks to
assess, which must be balanced with potential medical benefits.
The typical adverse effects of marijuana use may be outweighed by its
medical potential to treat many pain manifestations, and its potential benefits to
reducing opioid dependence and deaths. When used in conjunction with opiates,
cannabinoids can lead to a greater cumulative relief of pain, which can result in a
reduction in the use of opiate and associated side effects (Cichewicz et al., 1999).
Multiple studies indicate that cannabinoid receptors may interrupt signaling in the
opioid receptor systems, affecting craving for opiates and withdrawal severity
(Lucas, 2012). States with legalized marijuana laws have reported a reduction in
opioid use as evidenced by lower number of prescription opioid painkillers, reduced
number of opioid overdoses, and lower opioid-positive screens associated with car
fatalities (Hurd, 2017). The resulting public health benefits from reductions in
opioid use and treatment of chronic pain could include lower rates of alcoholrelated automobile accidents, reduced domestic violence, reductions in drug-related
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crimes, and reduced drug and alcohol-related morbidity and mortality (Lucas,
2012). Further than having an impact on patient pain levels and overall quality of
life, medical marijuana has the potential to reduce overall morbidity and mortality
associated with pharmaceutical opiates and opioid addiction.
Acceptance and Commitment Therapy
Chronic diseases and long-term conditions such as diabetes, HIV, cancer, or
brain injury have a detrimental effect on quality of life, mood, and overall wellbeing. This similarity indicates that well-being is affected by factors that are not
associated with the specific ailment, but rather perceptions of the illness, coping
strategies, self-efficacy, psychological flexibility, and emotion regulation (Graham et
al., 2016). Psychological flexibility is defined as being open, aware, and in contact
with the present moment, and flexibly engaging in behaviors which facilitate
overarching life goals. This psychological flexibility involves experiential acceptance,
contact with the present moment, self-as-context, values, and committed action.
Distress is considered a normal part of being human, manifest in self-doubt, fear,
uncertainty, self-criticism, negative thinking, and dysphoria. This is the theoretical
basis for Acceptance and Commitment Therapy (ACT), a newer form of Cognitive
Behavior Therapy that see one’s beliefs as the central process involved in therapy.
ACT does not aim to reduce distress per se, but rather to work through distress and
focus on values and goals rather than on problems. Individuals are encouraged to
allow their negative feelings, but try to identify what they can control and make
changes where they can (Barrett & Chang, 2016).

CHRONIC PAIN

19

Research around ACT proliferated in the past decade, and indicates that ACT
is associated with significant changes in acceptance, values-based action, and
mindfulness (Scott et al., 2016). As predicted, measures of committed action have
shown correlation with emotional well-being and general daily functioning (Scott et
al., 2016). Improvements have also been observed regarding pain, physical and
social functioning, and depression. Barrett and Chang (2016) found lower
depression, higher overall improvement ratings, higher pain acceptance, and no
change in pain severity or disability ratings.
While the total number of studies investigating ACT is low, the present
literature indicates a negative correlation between sample size and effect size,
meaning that the positive results found could be due to chance and small sample
sizes (Graham et al., 2016). Publishing bias likely keeps null results from being
published, furthering possible bias in the overall literature. The subjective nature of
the qualities that ACT targets require self-report from participants, which could also
skew results (Scott et al., 2016).
The Mid Valley Pain Clinic in Salem, Oregon serves to provide chronic pain
sufferers with pain management as well as treatment of emotional challenges
associated with chronic pain, and to educate patients regarding medical and nonmedical resources available to them. Treatment is offered in a 10-week course
format, where patients meet for a 3-hour session once a week. The 10-week
program includes a review of medications to assure optimal treatment, pain
management techniques to improve quality of life, setting goals to move from being
a chronic pain sufferer to a person living with chronic pain, training in relaxation,
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movement, coping, and managing pain, education about pain, medication, and
treatments, and the opportunity to share experiences and support with other
chronic pain sufferers.
Each weekly session begins with 1.5 hours of yoga, breathing, and
mindfulness exercises. Following movement therapy, the group moves to a
classroom for education regarding chronic pain and therapeutic activities. Following
the initial meeting, each week patients are assigned a chapter of reading from Living
Beyond Your Pain: Using Acceptance and Commitment Therapy to Ease Chronic
Pain (Dahl & Lundgren, 2006; See Appendix A).
The first meeting begins with education regarding the distinction between
acute and chronic pain and an introduction to mindfulness. Mindfulness requires
focusing one’s attention on what the individual is experiencing physically, mentally,
and emotionally in the present moment. The session continues with an overview of
relaxation techniques (deep, abdominal breathing, progressive muscle relaxation,
guided imagery, and biofeedback), and posture/body mechanics. The group
collectively participates in guided imagery led by the instructor, and practice proper
posture for various everyday situations: driving, cleaning, lifting, and laying down.
The second meeting begins with a look at the serenity creed: “Grant me the
courage to change the things I can, the serenity to accept the things I cannot change,
and the wisdom to know the difference,” (Dahl & Lundgren, 2006). This is followed
with an explanation of the “pain chain”: actual physical pain sensation, the mind’s
reaction to the pain, avoidance or escape behaviors based on the mind’s reaction,
and long-term choices based on avoidance and escape behaviors (Dahl & Lundgren,
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2006). Each participant establishes values that are important to them, and learn to
recognize and halt avoidance behaviors. Instructions for the use of ice and heat
treatments for pain are provided. A large portion of the meeting focuses on
communicating with primary care physicians regarding pain treatment, and
explaining the Pain Patient Bill of Rights (See Appendix B).
The third weekly meeting covers information regarding opioid treatment and
a brief overview of medical marijuana. The opioid treatment portion addresses the
effects of opiates and common side effects. Patients are informed that long term
treatment with opiates often requires a material risk notice for controlled
substances for intractable pain contract between the patient and doctor.
Distinctions are explored between addiction and dependence, and patients are
educated regarding aberrant drug-taking behaviors and how to avoid them.
Education regarding medical marijuana explains that many doctors are governed by
federal laws, and for this reason many primary care physicians do not condone
medical marijuana, nor can they prescribe it. The class closes with patients
considering which values are meaningful to them in their personal lives.
The fourth weekly meeting reviews the distinction between dependence and
addiction, and focuses on values and goals. The class goes over the importance of
setting goals and how to set achievable goals. With the values determined in the
previous meeting, patients work through how to turn their aspirations into
progression toward their personal values.
The fifth weekly meeting focuses on the power of thoughts. ACT is built on
the concept that an individual is not their thoughts (Dahl & Lundgren, 2006). Many
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patients live with the implicit attitude that they are a person with chronic pain, and
this concept governs their lives. Cognitive fusion refers to the blurred lines between
one’s thoughts and one’s sense of self. The group practices observing thoughts and
separating themselves from their thoughts.
The sixth weekly meeting dives deeper into mindfulness. Multiple relaxation
techniques are employed in an effort to practice mindfulness: repetitive motion,
word repetition, meditation, guided imagery, and deep breathing. The remainder of
the class explores the three senses of self that are identified in ACT: the
conceptualized self, the self as ongoing awareness, and the observer self. The
conceptualized self is the mentally defined concept an individual has of who they
are, the self as ongoing awareness refers to one’s sense of personal history, and the
observer self is always with the individual and will always be (Dahl & Lundgren,
2006).
The seventh weekly meeting addresses acceptance and willingness.
Acceptance as defined by ACT refers to the act by which one allows oneself to
willingly engage their pain (Dahl & Lundgren, 2006). Allowing pain to be and
focusing elsewhere allows one to focus on where they want to be and how to get
there. The remainder of the class involves imagining common difficult scenarios
from individual’s lives, and practicing using mindfulness to get through these
situations.
The eighth weekly meeting centers around committed action. Following
acceptance of pain, one can begin shaping the direction of your life instead of letting
pain be in control (Dahl & Lundgren, 2006). Acceptance offers a change in
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perspective, but commitment is required to enact the values that are important to
the individual. Acceptance allows the individual to recognize that they are in control,
and commitment is what it takes to get where one wants to be (Dahl & Lundgren,
2006).
The ninth weekly meeting explores alternative treatment methods.
Treatment methods covered included relaxation therapy, massage therapy,
chiropractic, aromatherapy, and acupuncture. Contact information is provided for
local providers of the treatment methods covered.
The final weekly session had patients create a unique, comprehensive pain
plan including as many treatment options as the patient chose from the “Pain
Management Shopping List”:
-

Guided imagery

-

Distraction

-

Continued group therapy

-

Meditation

-

Relaxation techniques

-

Continue to identify values and goals to reach them

-

Give a hug daily

-

Three deep breaths twice a day

-

Continue to use effective communication techniques with my doctor/build a
better relationship with my doctor

-

Work on developing good sleep habits

-

Get more exposure to sunlight

CHRONIC PAIN
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Take hot baths/showers

-

Eliminate or decrease alcohol

-

Eliminate or decrease caffeine

-

Eliminate or decrease smoking

-

Explore dietary supplements

-

Work on posture and body position

-

Walk 5 to 15 minutes a day

-

Local anesthetic creams

-

Ice

-

Monitor and treat medication side effects

-

Aromatherapy

-

Pacing

-

Community volunteering

-

Prayer or spirituality

-

Journaling or art

-

Keep a pain log

-

Using touch or vibration

-

Chiropractic

-

Acupuncture

-

Continued individual therapy

-

Maintain healthy body weight

Following completion of the 10-week program, participants were awarded
certificates of completion (See Appendix D).
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Discussion

Chronic pain can impair work, social, recreational, and household duties. It can have
a negative impact on financial security, familial, and marital relationships which
directly affects quality of life. It is clear that treatment is necessary for chronic pain
sufferers, but the current common treatments are often inadequate in isolation and
may cause more harm than good.
The dramatic increase in opioid misuse and addictions resulting from
increases in opioid prescriptions shows that opioid treatment is not an adequate
long-term treatment. Tolerance is quick to develop, and reductions in use produce
withdrawal symptoms. Even at its best, opioid treatment does not provide true
relief from all symptoms of chronic pain. As tolerance to the medication increases,
dosage can only safely increase to a certain degree, ultimately leaving the patient
with an addiction and without adequate pain relief. In addition, opioids do not
address the psychosocial issues that are often associated with chronic pain.
Research into the efficacy of medical marijuana treatment shows potential
for successfully treating chronic pain, but many questions remain unanswered.
Research into the medicinal benefits of cannabis is relatively new and the existent
literature is limited due to a lack of controlled studies. Like opioids, cannabis has
numerous side effects, though they are likely less dangerous and can be mitigated.
Side effects such as memory loss, depression, and anxiety responses require further
investigation into long-term effects.
The prevalence of studies investigating ACT is constantly growing, but is still
in its infancy. Compared to other common treatments for common pain, ACT has the
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fewest potential risks and is the only one to address the psychosocial ailments that
commonly co-occur with chronic pain. While ACT does address psychosocial factors,
physical pain relief may also be necessary in some cases. ACT is limited in that
treatment is expensive, access is limited, and success requires time and commitment
on the part of the patient. By emphasizing a psychological approach, there is the risk
of making both patients and physicians believe that pain is “all in their heads,”
delegitimizing pain. Widespread implementation of ACT would require a cultural
shift in how pain is perceived and how we think it should be treated.
Because chronic pain sufferers are a heterogeneous group, it is clear that
personalized treatment regimens are needed. This heterogeneity coupled with the
limits of current treatment methods indicate that the best treatment plan is one that
is multidisciplinary. Dowell and colleagues (2016) recommend beginning the
treatment process with nonpharmacological/non-opioid therapy, establishing
treatment goals for pain level and level of functioning, and beginning with the
lowest effective dose if opioid therapy is deemed appropriate. Biopsychosocial
treatment approaches have been shown to improve chronic pain, while targeting all
sources of distress/pain. While current treatments do show improvements, a
multidisciplinary treatment is best at quickly and effective reducing the negative
effects from chronic pain.
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Appendices
Appendix A

The 10-week course followed a book written by Joanne Dahl, Living Beyond Your
Pain: Using Acceptance and Commitment Therapy to Ease Chronic Pain.
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Appendix B

The 10-week course followed the above syllabus.
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Appendix C

The Patient Bill of Rights.

CHRONIC PAIN

36
Appendix D

Upon completion of the course, participants were awarded a certificate of
completion.

